期刊
BREAST CANCER RESEARCH
卷 9, 期 5, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/bcr1755
关键词
-
类别
资金
- NATIONAL CANCER INSTITUTE [T32CA009172] Funding Source: NIH RePORTER
- NCI NIH HHS [T32 CA009172] Funding Source: Medline
Neoadjuvant chemotherapy for breast cancer has a well-established role in the management of patients with locally advanced or early stage disease. Multiple trials have demonstrated superior survival outcomes in individuals achieving a pathologic complete response at the time of definitive surgery, and sophisticated genetic methods may predict which patients will be in this category. Those with less than a pathologic complete response remain at significant risk of recurrent disease, and currently no further standard therapy exists. Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据